Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SMC2 antisense RNA 1 (SMC2-AS1)
- Target
- SMC2-AS1
- Molecular classification
- Long non-coding RNA, antisense RNA, divergent transcript, non-protein coding transcript
01
Overview
SMC2-DT (SMC2 divergent transcript, also called SMC2-AS1) is a long non-coding RNA transcribed from the reverse strand near the SMC2 gene locus. Such divergent antisense lncRNAs commonly function as regulators of their neighboring genes by recruiting chromatin-modifying complexes and possibly influencing histone modification status. Unlike its protein-coding counterpart SMC2, which is an essential condensin complex subunit involved in mitosis and chromosome condensation, SMC2-DT acts at the RNA level and primarily serves as a molecular scaffold within the nucleus, modulating gene expression by epigenetic mechanisms. There is no evidence or reports currently implicating SMC2-DT directly as a protein target in drug discovery or as a receptor, enzyme, transporter, or classic therapeutic target.
- Other names
- SMC2-AS1SMC2-DTLOC105376193SMC2 divergent transcript
02
Mechanism of action
Not applicable (no known drugs directly act on SMC2-DT/SMC2-AS1)
03
Biological functions
Regulation of neighboring SMC2 gene expression (in cis)scaffold for recruitment of chromatin-modifying complexes regulating transcriptionpossible general involvement in epigenetic regulation
04
Disease associations
Potential roles in any condition where chromatin regulation and SMC2 gene activity matters, e.g. cell proliferation, cancer, genetic disorders, but specific links are not established in current literature
Beyond the preview
Go deeper on SMC2 antisense RNA 1 (SMC2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMC2 antisense RNA 1 (SMC2-AS1).